Literature DB >> 29185086

Interstitial lung disease in South Africans with systemic sclerosis.

Philippa Ashmore1, Mohammed Tikly1, Michelle Wong2, Claudia Ickinger3.   

Abstract

To investigate the frequency, severity and predictors of interstitial lung disease (ILD) in a cohort of South Africans with systemic sclerosis (SSc). Retrospective record review of SSc patients attending a tertiary Connective Tissue Diseases Clinic. Patients with ILD, defined by a combination of clinical findings, imaging, and lung function tests were compared to patients without ILD in terms of demographics, clinical features and autoantibodies. The majority (86.8%) of the 151 patients included were of Black ethnicity, 40% had ILD, of whom 39% had moderate-severe lung disease. Univariate predictors of ILD included: disease duration (OR 1.08, 95% CI 1.01-1.15); cough (OR 2.93, 95% CI 1.37-6.29); dyspnoea (OR 2.44, 95% CI 1.23-4.87); bibasal crackles (OR 7.58, 95% CI 3.31-17.37); diffuse cutaneous SSc (dcSSc) (OR 4.55, 95% CI 2.10-9.86) and a speckled anti-nuclear antibody (ANA) pattern (OR 2.47, 95% CI 1.25-4.90). Conversely, limited cutaneous disease (OR 0.22, 95% CI 0.09-0.50) and anti-centromere antibody (ACA) (OR 0.12, 95% CI 0.02-0.97) were protective. Independent predictors of ILD on multivariate analysis were bibasal crackles (OR 9.43, 95% CI 3.25-27.39), disease duration (OR 1.19, 95% CI 1.09-1.30) and speckled ANA (OR 2.95, 95% CI 1.22-7.15). Almost all (86.4%) patients received immunosuppressive treatment and the leading cause of death was related to ILD itself (44.4%). In this cohort of predominantly Black South Africans, SSc ILD was common and carried a poor prognosis. ILD occurred mainly, but not exclusively, in patients with dcSSc, especially those with a speckled ANA pattern. Conversely, the presence of ACA was protective against ILD.

Entities:  

Keywords:  Interstitial lung disease; Sub-Saharan Africa; Systemic sclerosis

Mesh:

Substances:

Year:  2017        PMID: 29185086     DOI: 10.1007/s00296-017-3893-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  24 in total

1.  Scleroderma in goldminers on the Witwatersrand with particular reference to pulmonary manifestations.

Authors:  L D ERASMUS
Journal:  S Afr J Lab Clin Med       Date:  1957-09

2.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

3.  Changes in causes of death in systemic sclerosis, 1972-2002.

Authors:  Virginia D Steen; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2007-02-28       Impact factor: 19.103

Review 4.  Interstitial lung disease in systemic sclerosis.

Authors:  Guillaume Bussone; Luc Mouthon
Journal:  Autoimmun Rev       Date:  2010-09-21       Impact factor: 9.754

Review 5.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

6.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

7.  Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort.

Authors:  Shervin Assassi; Roozbeh Sharif; Robert E Lasky; Terry A McNearney; Rosa M Estrada-Y-Martin; Hilda Draeger; Deepthi K Nair; Marvin J Fritzler; John D Reveille; Frank C Arnett; Maureen D Mayes
Journal:  Arthritis Res Ther       Date:  2010-09-02       Impact factor: 5.156

Review 8.  Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management.

Authors:  Flavia V Castelino; John Varga
Journal:  Arthritis Res Ther       Date:  2010-08-23       Impact factor: 5.156

9.  A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis.

Authors:  Virginia Steen; Robyn T Domsic; Mary Lucas; Noreen Fertig; Thomas A Medsger
Journal:  Arthritis Rheum       Date:  2012-09

10.  Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database.

Authors:  Florian M P Meier; Klaus W Frommer; Robert Dinser; Ulrich A Walker; Laszlo Czirjak; Christopher P Denton; Yannick Allanore; Oliver Distler; Gabriela Riemekasten; Gabriele Valentini; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2012-05-21       Impact factor: 19.103

View more
  6 in total

Review 1.  Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review.

Authors:  Anna-Maria Hoffmann-Vold; Toby M Maher; Edward E Philpot; Ali Ashrafzadeh; Oliver Distler
Journal:  ERJ Open Res       Date:  2021-02-22

Review 2.  Mitochondria, Aging, and Cellular Senescence: Implications for Scleroderma.

Authors:  Marta Bueno; Anna Papazoglou; Eleanor Valenzi; Mauricio Rojas; Robert Lafyatis; Ana L Mora
Journal:  Curr Rheumatol Rep       Date:  2020-06-19       Impact factor: 4.592

3.  Clinical and laboratory features of African-Brazilian patients with systemic sclerosis.

Authors:  Cristiane Mendes; Vilma S T Viana; Sandra G Pasoto; Elaine P Leon; Eloisa Bonfa; Percival D Sampaio-Barros
Journal:  Clin Rheumatol       Date:  2019-05-07       Impact factor: 2.980

4.  Autoantibodies as biomarkers for interstitial lung disease in idiopathic inflammatory myositis and systemic sclerosis: The case of anti-eIF2B antibodies.

Authors:  Angela Ceribelli; Natasa Isailovic; Maria De Santis; Carolina Gorlino; Minoru Satoh; Carlo Selmi
Journal:  J Transl Autoimmun       Date:  2020-03-31

5.  Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.

Authors:  Dinesh Khanna; Donald P Tashkin; Christopher P Denton; Elisabetta A Renzoni; Sujal R Desai; John Varga
Journal:  Am J Respir Crit Care Med       Date:  2020-03-15       Impact factor: 21.405

6.  Interstitial lung disease in patients with connective tissue disease: Subtypes, clinical features and comorbidities in the Western Cape, South Africa.

Authors:  E Palalane; D Alpizar-Rodriguez; S Botha; Q Said-Hartley; G Calligaro; B Hodkinson
Journal:  Afr J Thorac Crit Care Med       Date:  2022-07-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.